Pde inhibitors for the treatment of hearing impairment

A technology of inhibitors and therapeutic agents, applied in the field of the treatment of hearing impairment and PDE-5 inhibitors, can solve problems such as no clinical confirmation

Inactive Publication Date: 2010-05-19
BAYER SCHERING PHARMA AG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, there are no clinically proven medications for the treatment of tinnitus and hearing loss (sensorineural and neuropathic), and such medications are greatly needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pde inhibitors for the treatment of hearing impairment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] All animal experiments were performed in accordance with the German Laboratory Animal Protection Act and were performed in accordance with approved animal health and welfare guidelines. Experiments were performed using female Sprague Dawley rats weighing between 300-400 g. To induce acoustic trauma (AT), animals were kept under anesthesia (ketamine, xylazine, xylazine (Rompun) i.p. injection) and exposed to band noise or pure tones generated using a calibrated microphone in a reverberation chamber. The sound consists of a continuous 10kHz tone at 115dB SPL. All auditory stimuli were scaled at the level of the animal's head. With vardenafil [10 mg / kg / p.o. dissolved in ethanol / Solutol / water (10 / 40 / 50), using a volume of 5ml / kg] or placebo [ethanol / Solutol / water (10 / 40 / 50), Rats were treated twice daily using a volume of 5 ml / kg]. The first treatment with vardenafil or placebo was 1 hour before AT. Hearing thresholds were measured by recording brainstem auditory respon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides pharmacological compositions comprising PDE-5 inhibitors for the treatment of hearing impairment i.e. hearing loss and tinnitus. The invention also provides methods of screening for such PDE-5 inhibitors for use in the preparation of medicaments for the treatment of hearing impairment i.e. hearing loss and tinnitus.

Description

[0001] technical field of invention [0002] The present invention relates to the pharmacology of phosphodiesterases (PDEs) and PDE inhibitors. More specifically, the present invention relates to PDE-5 inhibitors and their use in the manufacture of a medicament for the treatment of hearing impairment, ie hearing loss and tinnitus. Background of the invention [0003] Hearing impairment, ie loss of hearing and tinnitus, affects more than 250 million patients worldwide and is therefore a very common disease. Hearing impairment significantly reduces the patient's quality of life and is currently still not adequately treated. Hearing loss can generally be divided into conductive hearing loss, sensorineural hearing loss, and mixed hearing loss, which is a combination of conductive and sensorineural hearing loss. Conductive hearing loss results from damage to the outer or middle ear, ie, from an ear infection. Sensorineural hearing loss includes sensorineural hearing loss caused ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/00C12Q1/44
CPCG01N2500/04C12Q1/44G01N2333/916G01N2800/14A61K31/53A61P27/16A61P43/00A61K31/519A61K31/4985
Inventor P·桑德纳J·赫特
Owner BAYER SCHERING PHARMA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap